CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,203 enrolled
Drug / intervention
RX Acculink Carotid Stent System (RX Acculink)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01445613
NCT01445613N/ACompleted
CompareCT.gov

CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

Abbott Medical Devices·interventional·Posted Oct 4, 2011·Updated Aug 12, 2016

In Brief

A clinical study evaluating RX Acculink Carotid Stent System (RX Acculink) for Carotid Artery Disease and 3 related conditions. Completed, enrolled 1,203 participants across 1 site.

Detailed Summary

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 4, 2011
Enrollment StartOct 1, 2011
Primary CompletionDec 1, 2014
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.7 years ago

Interventions

RX Acculink Carotid Stent System (RX Acculink)device

Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.